Plain language summary of the first etavopivat clinical study in sickle cell disease

This Plain Language Summary of Publication article (PLSP) from Future Rare Diseases describes the first clinical study of etavopivat, a potential treatment for sickle cell disease (SCD). SCD is an inherited condition where red blood cells become sickle-shaped, making them poor at carrying oxygen and causing blood vessel blockages. The study tested daily etavopivat tablets in a small group of SCD patients to determine tolerable doses, side effects, and effects on red blood cell shape and function.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease’ and was published in Blood Advances.

Visit Ash Publications using the link to read the original article.

• etavopivat
• lay summary
• Phase 1
• plain language summary
• SCD
• sickle cell anemia
• sickle cell disease